Healthcare alliance for resourceful medicines offensive against neoplasms in hematology – PLUS


Haematological malignancies, also known as blood cancers, are a diverse and complex group of diseases that are difficult to diagnose and treat. Nowadays most treatments are extremely complex, and advances in patient diagnosis and treatment are slow due to the low number of patients per centre. There is therefore a need to harmonise, store, and analyse the current information on these diseases to speed up and support the decision-making process for patient access to new therapies.

IMI’s HARMONY project is using big data to advance our understanding of the following seven blood cancers: acute lymphoblastic leukaemia (ALL); acute myeloid leukaemia (AML); chronic lymphocytic leukaemia (CLL); multiple myeloma (MM); myelodysplastic syndromes (MDS); non-Hodgkin lymphoma (NHL); and paediatric haematologic malignancies. HARMONY has set up a Big Data platform to support its work.

The aim of HARMONY PLUS is to build on HARMONY’s work. Firstly, it will add the following blood cancers to the list of diseases under study: chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; as well as Hodgkin’s lymphoma, Waldenström macroglobulinemia and other rare blood cancers not covered by HARMONY.

In addition, HARMONY PLUS will help to convert the existing HARMONY platform into an integrated services platform that could serve clinicians to improve their decision making process and support clinical trial design, among other things.

Like HARMONY, HARMONY PLUS is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.

Achievements & News


  Show participants on map
EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Celgene Management SARL, Couvet, Switzerland
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Menarini Ricerche S.A, Pomezia, Italy
  • Novartis Pharma AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
  • Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy
  • Bundesinstitut Fur Arzneimittel Und Medizinprodukte, Bonn, Germany
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • European Research Initiative On Cll Ev, Köln, Germany
  • European Society For Blood And Marrow Transplantation, Leiden, Netherlands
  • Fondazione Italiana Sindromi Mielodisplastiche Ets, Alessandria, Italy
  • Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Barcelona, Spain
  • Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon, Soria, Spain
  • Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain
  • Genome Research Limited, London, United Kingdom
  • Groupe Francophone Des Myelodysplasies, Paris, France
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Masarykova univerzita, Brno, Czech Republic
  • National Institute For Health And Care Excellence, Manchester, United Kingdom
  • Ospedale Pediatrico Bambino Gesu, Rome, Italy
  • Stichting Amsterdam Umc, Amsterdam, Netherlands
  • Stiftung Eln Foundation, Weinheim, Germany
  • The Lymphoma Study Association, Pierre Benite, France
  • Universidad De Navarra, Pamplona, Spain
  • Universita Degli Studi Di Torino, Turin, Italy
  • Universitaet Ulm, Ulm, Germany
  • University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
  • University of Helsinki, University of Helsinki, Helsinki, Finland
  • Vib Vzw, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • European Hematology Association, The Hague, Netherlands
  • Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain
  • Gpoh Gemeinnutzige GMBH, Hannover, Germany
  • Mll Munchner Leukamielabor GMBH, Munich, Germany
  • Synapse Research Management Partners SL, Barcelona, Spain
Patient organisations
  • Leukanet Ev, Riemerling, Germany
Third parties
  • Istituto Nazionale Di Fisica Nucleare, Frascati, Italy
  • Lysarc, Pierre-Benite, France

NameEU funding in €
Agencia Espanola De Medicamentos Y Productos Sanitarios75 750
Alma Mater Studiorum - Universita Di Bologna239 000
Bundesinstitut Fur Arzneimittel Und Medizinprodukte11 250
Charite - Universitaetsmedizin Berlin335 250
Erasmus Universitair Medisch Centrum Rotterdam90 000
European Hematology Association664 250
European Research Initiative On Cll Ev90 000
European Society For Blood And Marrow Transplantation121 250
Fondazione Italiana Sindromi Mielodisplastiche Ets90 000
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras90 000
Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon1 606 368
Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana405 000
Genome Research Limited54 000
Gmv Soluciones Globales Internet Sau502 500
Gpoh Gemeinnutzige GMBH90 000
Groupe Francophone Des Myelodysplasies90 000
Leukanet Ev276 125
Ludwig-Maximilians-Universitaet Muenchen90 000
Masarykova univerzita54 000
Medisapiens Oy (left the project)32 632
Mll Munchner Leukamielabor GMBH54 000
National Institute For Health And Care Excellence328 500
Ospedale Pediatrico Bambino Gesu90 000
Stichting Amsterdam Umc90 000
Stiftung Eln Foundation90 000
Synapse Research Management Partners SL307 750
The Lymphoma Study Association18 750
Universidad De Navarra90 000
Universita Degli Studi Di Torino90 000
Universitaet Ulm90 000
University of Cambridge90 000
University of Helsinki54 000
University Of Newcastle Upon Tyne90 000
Vib Vzw54 000
Third parties
NameFunding in €
Istituto Nazionale Di Fisica Nucleare100 000
Lysarc71 250
Total Cost6 715 625